The  ||| S:0 E:4 ||| DT
use  ||| S:4 E:8 ||| NN
of  ||| S:8 E:11 ||| IN
thiazides  ||| S:11 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
chronic  ||| S:24 E:32 ||| JJ
kidney  ||| S:32 E:39 ||| NN
disease  ||| S:39 E:47 ||| NN
Hypertension  ||| S:47 E:60 ||| NNP
is  ||| S:60 E:63 ||| VBZ
often  ||| S:63 E:69 ||| RB
difficult  ||| S:69 E:79 ||| JJ
to  ||| S:79 E:82 ||| TO
control  ||| S:82 E:90 ||| VB
in  ||| S:90 E:93 ||| IN
patients  ||| S:93 E:102 ||| NNS
with  ||| S:102 E:107 ||| IN
chronic  ||| S:107 E:115 ||| JJ
kidney  ||| S:115 E:122 ||| NN
disease ||| S:122 E:129 ||| NN
.  ||| S:129 E:131 ||| .
Clinicians  ||| S:131 E:142 ||| NNP
often  ||| S:142 E:148 ||| RB
view  ||| S:148 E:153 ||| VB
thiazide  ||| S:153 E:162 ||| NNS
and  ||| S:162 E:166 ||| CC
thiazide-like  ||| S:166 E:180 ||| JJ
diuretics  ||| S:180 E:190 ||| NN
as  ||| S:190 E:193 ||| IN
being  ||| S:193 E:199 ||| VBG
ineffective  ||| S:199 E:211 ||| NN
in  ||| S:211 E:214 ||| IN
reducing  ||| S:214 E:223 ||| VBG
blood  ||| S:223 E:229 ||| NN
pressure  ||| S:229 E:238 ||| NN
in  ||| S:238 E:241 ||| IN
patients  ||| S:241 E:250 ||| NNS
with  ||| S:250 E:255 ||| IN
chronic  ||| S:255 E:263 ||| JJ
kidney  ||| S:263 E:270 ||| NN
disease ||| S:270 E:277 ||| NN
,  ||| S:277 E:279 ||| ,
and  ||| S:279 E:283 ||| CC
prefer  ||| S:283 E:290 ||| VB
to  ||| S:290 E:293 ||| TO
use  ||| S:293 E:297 ||| VB
loop  ||| S:297 E:302 ||| JJ
diuretics ||| S:302 E:311 ||| NN
,  ||| S:311 E:313 ||| ,
especially  ||| S:313 E:324 ||| RB
if  ||| S:324 E:327 ||| IN
the  ||| S:327 E:331 ||| DT
estimated  ||| S:331 E:341 ||| JJ
glomerular  ||| S:341 E:352 ||| JJ
filtration  ||| S:352 E:363 ||| JJ
rate  ||| S:363 E:368 ||| NN
( ||| S:368 E:369 ||| -LRB-
eGFR ||| S:369 E:373 ||| NNP
)  ||| S:373 E:375 ||| -RRB-
is  ||| S:375 E:378 ||| VBZ
below  ||| S:378 E:384 ||| IN
50  ||| S:384 E:387 ||| CD
ml ||| S:387 E:389 ||| FW
/ ||| S:389 E:390 ||| FW
min ||| S:390 E:393 ||| FW
/ ||| S:393 E:394 ||| FW
1.73m ||| S:394 E:399 ||| FW
( ||| S:399 E:400 ||| -LRB-
2 ||| S:400 E:401 ||| LS
) ||| S:401 E:402 ||| -RRB-
.  ||| S:402 E:404 ||| .
Recent  ||| S:404 E:411 ||| JJ
clinical  ||| S:411 E:420 ||| JJ
trial  ||| S:420 E:426 ||| NN
data  ||| S:426 E:431 ||| NNS
indicate  ||| S:431 E:440 ||| VBP
that  ||| S:440 E:445 ||| DT
thiazide  ||| S:445 E:454 ||| NN
and  ||| S:454 E:458 ||| CC
thiazide-like  ||| S:458 E:472 ||| JJ
diuretics  ||| S:472 E:482 ||| NNS
possess  ||| S:482 E:490 ||| VBP
important  ||| S:490 E:500 ||| JJ
and  ||| S:500 E:504 ||| CC
clinically  ||| S:504 E:515 ||| RB
significant  ||| S:515 E:527 ||| JJ
antihypertension  ||| S:527 E:544 ||| JJ
properties ||| S:544 E:554 ||| NNS
,  ||| S:554 E:556 ||| ,
that  ||| S:556 E:561 ||| WDT
are  ||| S:561 E:565 ||| VBP
likely  ||| S:565 E:572 ||| RB
independent  ||| S:572 E:584 ||| JJ
of  ||| S:584 E:587 ||| IN
volume  ||| S:587 E:594 ||| NN
reduction ||| S:594 E:603 ||| NN
,  ||| S:603 E:605 ||| ,
even  ||| S:605 E:610 ||| RB
in  ||| S:610 E:613 ||| IN
patients  ||| S:613 E:622 ||| NNS
with  ||| S:622 E:627 ||| IN
eGFR  ||| S:627 E:632 ||| JJ
in  ||| S:632 E:635 ||| IN
the  ||| S:635 E:639 ||| DT
15-45  ||| S:639 E:645 ||| FW
ml ||| S:645 E:647 ||| FW
/ ||| S:647 E:648 ||| FW
min  ||| S:648 E:652 ||| FW
range ||| S:652 E:657 ||| NN
.  ||| S:657 E:659 ||| .
Thiazide  ||| S:659 E:668 ||| NNP
and  ||| S:668 E:672 ||| CC
thiazide-like  ||| S:672 E:686 ||| JJ
diuretics  ||| S:686 E:696 ||| NN
should  ||| S:696 E:703 ||| MD
be  ||| S:703 E:706 ||| VB
given  ||| S:706 E:712 ||| VBN
consideration  ||| S:712 E:726 ||| NN
for  ||| S:726 E:730 ||| IN
use  ||| S:730 E:734 ||| NN
in  ||| S:734 E:737 ||| IN
the  ||| S:737 E:741 ||| DT
treatment  ||| S:741 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
hypertension  ||| S:754 E:767 ||| NN
in  ||| S:767 E:770 ||| IN
patients  ||| S:770 E:779 ||| NNS
with  ||| S:779 E:784 ||| IN
chronic  ||| S:784 E:792 ||| JJ
kidney  ||| S:792 E:799 ||| NN
disease ||| S:799 E:806 ||| NN
,  ||| S:806 E:808 ||| ,
especially  ||| S:808 E:819 ||| RB
if  ||| S:819 E:822 ||| IN
there  ||| S:822 E:828 ||| EX
is  ||| S:828 E:831 ||| VBZ
no  ||| S:831 E:834 ||| DT
clinical  ||| S:834 E:843 ||| JJ
evidence  ||| S:843 E:852 ||| NN
of  ||| S:852 E:855 ||| IN
volume  ||| S:855 E:862 ||| NN
overload ||| S:862 E:870 ||| NN
.  ||| S:870 E:872 ||| .
